Melanomas are a major cause of premature death from cancer. The gradual decrease in rates of morbidity and mortality has occurred as a result of public health campaigns and improved rates of early diagnosis. Survival of melanoma has increased to over 90%. Management of melanoma involves a number of components: excision, tumor staging, re-excision with negative margins, adjuvant therapies (chemo, radiation or surgery), treatment of stage IV disease, follow-up examination for metastasis, lifestyle modification and counseling. Sentinel lymph node status is an important prognostic factor for survival in patients with a melanoma >1 mm. However, sentinel lymph node biopsies have received partial support due to the limited data regarding the survival advantage of complete lymph node dissection when a micrometastasis is detected in the lymph nodes. Functional mutations in the mitogen-activated pathways are commonly detected in melanomas and these influence the growth control. Therapies that target these pathways are rapidly emerging, and are being shown to increase survival rates in patients. Access to these newer agents can be gained by participation in clinical trials after referral to a multidisciplinary team for staging and re-excision of the scar.
References
[1]
Gandini, S.; Sera, F.; Cattaruzza, M.S.; Pasquini, P.; Zanetti, R.; Masini, C.; Boyle, P.; Melchi, C.F. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur. J. Cancer 2005, 41, 2040–2059, doi:10.1016/j.ejca.2005.03.034.
[2]
Gandini, S.; Sera, F.; Cattaruzza, M.S.; Pasquini, P.; Picconi, O.; Boyle, P.; Melchi, C.F. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur. J. Cancer 2005, 41, 45–60, doi:10.1016/j.ejca.2004.10.016.
[3]
Gandini, S.; Sera, F.; Cattaruzza, M.S.; Pasquini, P.; Abeni, D.; Boyle, P.; Melchi, C.F. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur. J. Cancer 2005, 41, 28–44, doi:10.1016/j.ejca.2004.10.015.
[4]
Bataille, V. Early detection of melanoma improves survival. Practitioner 2009, 253, 29–32.
[5]
Australian Institute of Health and Welfare. Cancer in Australia: An Overview 2012; AIHW: Canberra, Australia, 2012.
[6]
Australian Bureau of Statistics. Mortality and Morbidity: Cancer Trends; ABS: Canberra, Australia, 2004.
[7]
Shah, G.D.; Chapman, P.B. Adjuvant therapy of melanoma. Cancer J. 2007, 13, 217–222, doi:10.1097/PPO.0b013e318074dfd4.
[8]
Creagan, E.T.; Dalton, R.J.; Ahmann, D.L.; Jung, S.H.; Morton, R.F.; Langdon, R.M., Jr.; Kugler, J.; Rodrigue, L.J. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J. Clin. Oncol. 1995, 13, 2776–2783.
[9]
White, R.R.; Stanley, W.E.; Johnson, J.L.; Tyler, D.S.; Seigler, H.F. Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann. Surg. 2002, 235, 879–887, doi:10.1097/00000658-200206000-00017.
[10]
Balch, C.M.; Soong, S.J.; Gershenwald, J.E.; Thompson, J.F.; Reintgen, D.S.; Cascinelli, N.; Urist, M.; McMasters, K.M.; Ross, M.I.; Kirkwood, J.M.; et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 2001, 19, 3622–3634.
[11]
Tas, F. Metastatic behavior in melanoma: Timing, pattern, survival, and influencing factors. J. Oncol. 2012, 2012, e647684.
[12]
Stark, M.S.; Woods, S.L.; Gartside, M.G.; Bonazzi, V.F.; Dutton-Regester, K.; Aoude, L.G.; Chow, D.; Sereduk, C.; Niemi, N.M.; Tang, N.; et al. Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat. Genet. 2012, 44, 165–169.
[13]
Wagner, J.D.; Ranieri, J.; Evdokimow, D.Z.; Logan, T.; Chuang, T.Y.; Johnson, C.S.; Jung, S.H.; Wenck, S.; Coleman, J.J. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. Plast Reconstr. Surg. 2003, 112, 486–497, doi:10.1097/01.PRS.0000070989.23469.1F.
[14]
Morton, D.L.; Thompson, J.F.; Cochran, A.J.; Mozzillo, N.; Elashoff, R.; Essner, R.; Nieweg, O.E.; Roses, D.; Hoekstra, H.; Karakousis, C.; et al. Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med. 2006, 355, 1307–1317, doi:10.1056/NEJMoa060992.
[15]
Satzger, I.; Volker, B.; Meier, A.; Schenck, F.; Kapp, A.; Gutzmer, R. Prognostic significance of isolated HMB45 or Melan A positive cells in Melanoma sentinel lymph nodes. Am. J. Surg. Path. 2007, 31, 1175–1180, doi:10.1097/PAS.0b013e3180341ebc.
[16]
Davies, M.A.; Samuels, Y. Analysis of the genome to personalize therapy for melanoma. Oncogene 2010, 29, 5545–5555, doi:10.1038/onc.2010.323.
[17]
Kelleher, F.C.; McArthur, G.A. Targeting NRAS in melanoma. Cancer J. 2012, 18, 132–136, doi:10.1097/PPO.0b013e31824ba4df.
[18]
Flaherty, K.T.; Hodi, F.S.; Fisher, D.E. From genes to drugs: Targeted strategies for melanoma. Nat. Rev. Cancer 2012, 12, 349–361, doi:10.1038/nrc3218.
[19]
Michalik, E.E.; Fitzpatrick, T.B.; Sober, A.J. Rapid progression of lentigo maligna to deeply invasive lentigo maligna melanoma. Report of two cases. Arch. Dermatol. 1983, 119, 831–835, doi:10.1001/archderm.1983.01650340041017.
Van Raamsdonk, C.D.; Bezrookove, V.; Green, G.; Bauer, J.; Gaugler, L.; O’Brien, J.M.; Simpson, E.M.; Barsh, G.S.; Bastian, B.C. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009, 457, 599–602, doi:10.1038/nature07586.
[22]
Van Raamsdonk, C.D.; Griewank, K.G.; Crosby, M.B.; Garrido, M.C.; Vemula, S.; Wiesner, T.; Obenauf, A.C.; Wackernagel, W.; Green, G.; Bouvier, N.; et al. Mutations in GNA11 in uveal melanoma. N. Engl. J. Med. 2010, 363, 2191–2199, doi:10.1056/NEJMoa1000584.
[23]
Longo, C.; Rito, C.; Beretti, F.; Cesinaro, A.M.; Pineiro-Maceira, J.; Seidenari, S.; Pellacani, G. De novo melanoma and melanoma arising from pre-existing nevus: In vivo morphologic differences as evaluated by confocal microscopy. J. Am. Acad. Dermatol. 2011, 65, 604–614, doi:10.1016/j.jaad.2010.10.035.
[24]
Soyer, H.P.; Argenziano, G.; Hofmann-Wellenhof, R.; Zalaudek, I. Dermoscopy: The Essentials, 2nd ed. ed.; Elsevier: London, UK, 2011.
[25]
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Melanoma. V2.2009; NCCN: Fort Washington, PA, USA, 2008.
[26]
Balch, C.M.; Gershenwald, J.E.; Soong, S.J.; Thompson, J.F.; Atkins, M.B.; Byrd, D.R.; Buzaid, A.C.; Cochran, A.J.; Coit, D.G.; Ding, S.; et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 2009, 27, 6199–6206, doi:10.1200/JCO.2009.23.4799.
[27]
Australian Cancer Network. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand; Cancer Council Australia and Australian Cancer Network and New Zealand Guidelines Group: Sydney, Australia, Wellington, New Zealand, 2008.
[28]
Kirkwood, J.M.; Richards, T.; Zarour, H.M.; Sosman, J.; Ernstoff, M.; Whiteside, T.L.; Ibrahim, J.; Blum, R.; Wieand, S.; Mascari, R. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: The E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer 2002, 95, 1101–1112, doi:10.1002/cncr.10775.
[29]
Tarhini, A.A.; Gogas, H.; Kirkwood, J.M. IFN-α in the treatment of melanoma. J. Immunol. 2012, 189, 3789–3793, doi:10.4049/jimmunol.1290060.
[30]
Kirkwood, J.M.; Strawderman, M.H.; Ernstoff, M.S.; Smith, T.J.; Borden, E.C.; Blum, R.H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 1996, 14, 7–17.
[31]
Kirkwood, J.M.; Manola, J.; Ibrahim, J.; Sondak, V.; Ernstoff, M.S.; Rao, U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. 2004, 10, 1670–1677, doi:10.1158/1078-0432.CCR-1103-3.
[32]
Wheatley, K.; Ives, N.; Hancock, B.; Gore, M.; Eggermont, A.; Suciu, S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat. Rev. 2003, 29, 241–252, doi:10.1016/S0305-7372(03)00074-4.
[33]
Mocellin, S.; Lens, M.B.; Pasquali, S.; Pilati, P.; Chiarion Sileni, V. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst. Rev. 2013, doi:10.1002/14651858.CD008955.pub2.
[34]
Di Trolio, R.; Simeone, E.; di Lorenzo, G.; Grimaldi, A.M.; Romano, A.; Ayala, F.; Caracò, C.; Mozzillo, N.; Ascierto, P.A. Update on PEG-interferon α-2b as adjuvant therapy in melanoma. Anticancer Res. 2012, 32, 3901–3909.
[35]
Lens, M.B.; Dawes, M. Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: A systematic review of randomised controlled trials. Lancet Oncol. 2003, 4, 359–364, doi:10.1016/S1470-2045(03)01117-3.
[36]
Hodi, F.S.; O’Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Shadendorf, D.; Hassel, J.; et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363, 711–723, doi:10.1056/NEJMoa1003466.
[37]
Pennock, G.K.; Waterfield, W.; Wolchock, J.D. Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: How different are these from conventional treatment responses? Am. J. Clin. Oncol. 2012, 35, 606–611.
[38]
Wolchok, J.D.; Weber, J.S.; Maio, M.; Neyns, B.; Harmankaya, K.; Chin, K.; Cykowski, L.; de Pril, V.; Humphrey, R.; Lebbe, C. Four-year survival rates for patients with metastatic melanoma who received implimumab in phase II clinical trials. Ann. Oncol. 2013, 24, 2174–2180, doi:10.1093/annonc/mdt161.
[39]
Robert, C.; Thomas, L.; Bondarenko, I.; O’Day, S.; Weber, J.; Garbe, C.; Lebbe, C.; Baurain, J.F.; Testori, A.; Grob, J.J.; et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364, 2517–2526, doi:10.1056/NEJMoa1104621.
[40]
US Food and Drug Administration. FDA News Release. U.S. Department of Health and Human Services, 2011. 2011. Available online: www.fda.gov/ (accessed on 22 October 2013).
[41]
Wolchok, J.D.; Kluger, H.; Callahan, M.K.; Postow, M.A.; Rizvi, N.A.; Lesokhin, A.M.; Segal, N.; Ariyan, C.; Gordon, R.; Reed, K.; et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369, 122–133, doi:10.1056/NEJMoa1302369.
[42]
Sznol, M.; Kluder, H.; Hodi, S.; McDermott, D.; Carvajal, R.; Lawrence, D.P.; Topalian, S.; Atkins, M.; Powderly, J.; Sharfman, W.; et al. Survival and Long-Term Follow-up of Safety and Response in Patients (pts) with Advanced Melanoma (MEL) in a Phase I Trial of Nivolumab (anti-PD-1; BMS-936558;ONO-4538). In Proceedings of 2013 ASCO Annual Meeting, Chicago, IL, USA, 31 May–4 June 2013.
[43]
Wolchok, J.D.; Kluger, H.; Callahan, M.K.; Postow, M.A.; Gordon, R.; Segal, N.H.; Lesokhin, A.M.; Reed, K.; Burke, M.; Caldwell, A.; et al. Clinical Activity and Safety of Nivolumab(anti-PD-1, BMS-936558, ONO-4538) Incombination with Ipilimumab in Patients with Advanced Melanoma. In Proceedings of 2013 ASCO Annual Meeting, Chicago, IL, USA, 31 May–4 June 2013.
[44]
Sosman, J.A.; Kim, K.B.; Schuchter, L.; Gonzalez, R.; Pavlick, A.C.; Weber, J.S.; McArthur, G.; Hutson, T.; Moschos, S.; Flaherty, K.; et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 2012, 366, 707–714, doi:10.1056/NEJMoa1112302.
[45]
Das, T.M.; Salangsang, F.; Landman, A.S.; Sellers, W.R.; Pryer, N.K.; Levesque, M.P.; Dummer, R.; McMahon, M.; Stuart, D. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013, 494, 251–255, doi:10.1038/nature11814.
[46]
Huang, V.; Hepper, D.; Anadkat, M.; Cornelius, L. Cutaneous toxic effects associated with emurafenib and inhibition of the BRAF pathway. Arch. Dermatol. 2012, 148, 628–633.
[47]
Chu, E.Y.; Wanat, K.A.; Miller, C.J.; Amaravadi, R.K.; Fecher, L.A.; Brose, M.S.; McGettigan, S.; Giles, L.R.; Schuchter, L.M.; Seykora, J.T.; et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study. J. Am. Acad. Dermatol. 2012, 67, 1265–1272, doi:10.1016/j.jaad.2012.04.008.
[48]
Falchook, G.S.; Trent, J.C.; Heinrich, M.C.; Beadling, C.; Patterson, J.; Bastida, C.C.; Blackman, S.C.; Kurzrock, R. BRAF mutant gastrointestinal stromal tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget 2013, 4, 310–315.
[49]
GlaxoSmithKline. Two New GSK Oral Oncology Treatmens, BRAF-Inhibitor Tafinlar (Dabrafenib) Capsules and the First MEK-Inhibitor Mekinist (Trametinib) Tablets, Approved by FDA as Single-Agent Therapies. Available online: http://us.gsk.com/html/media-news/pressreleases/2013/2013-pressrelease-1350998.htm/ (accessed on 22 October 2013).
[50]
Patrawala, S.; Puzanov, I. Vemurafenib (RG67204, PLX4032): A potent, selective BRAF kinase inhibitor. Future Oncol. 2012, 8, 509–523.
Ribas, A.; Hodi, F.S.; Callahan, M.; Konto, C.; Wolchok, J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 2013, 368, 1365–1366, doi:10.1056/NEJMc1302338.
[53]
Khattak, M.; Fisher, R.; Turajlic, S.; Larkin, J. Targeted therapy and immunotherapy in advanced melanoma: An evolving paradigm. Ther. Adv. Med. Oncol. 2013, 5, 105–118, doi:10.1177/1758834012466280.
[54]
Gibney, G.T.; Zager, J.S. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. Expert Opin. Drug Metab. Toxicol. 2013, 9, 893–899, doi:10.1517/17425255.2013.794220.
Flaherty, K.T.; Robert, C.; Hersey, P.; Nathan, P.; Garbe, C.; Milhem, M.; Demidov, L.V.; Hassel, J.C.; Rutkowski, P.; Mohr, P.; et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 2012, 367, 107–114, doi:10.1056/NEJMoa1203421.
[57]
Kirkwood, J.M.; Bastholt, L.; Robert, C.; Sosman, J.; Larkin, J.; Hersey, P.; Middleton, M.; Cantarini, M.; Zazulina, V.; Kemsley, K.; et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res. 2012, 18, 555–567, doi:10.1158/1078-0432.CCR-11-1491.
[58]
Chapman, P.B.; Einhornm, L.H.; Meyers, M.L.; Saxman, S.; Destro, A.N.; Panageas, K.S.; Begg, C.B.; Abarwala, S.S.; Schuchter, L.M.; Ernstoff, M.S.; et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol. 1999, 17, 2745–2751.
[59]
Middleton, M.R.; Grob, J.J.; Aaronson, N.; Fierlbeck, G.; Tilgen, W.; Seiter, S.; Gore, M.; Aamdal, S.; Cebon, J.; Coates, A.; et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 2000, 18, 158–166.
[60]
Avril, M.F.; Aamdal, S.; Grob, J.J.; Hauschild, A.; Mohr, P.; Bonerandi, J.J.; Weichenthal, M.; Neuber, K.; Bieber, T.; Gilde, K.; et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study. J. Clin. Oncol. 2004, 22, 1118–1125, doi:10.1200/JCO.2004.04.165.
[61]
Flaherty, K.T.; Infante, J.R.; Daud, A.; Gonzalez, R.; Kefford, R.F.; Sosman, J.; Hamid, O.; Schuchter, L.; Cebon, J.; Ibrahim, N.; et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 2012, 367, 1694–1703, doi:10.1056/NEJMoa1210093.
[62]
Sosman, J.A.; Daud, A.; Weber, J.S.; Kim, K.; Kefford, R.; Flaherty, K.; Infante, J.R.; Hamid, O.; Cebon, J.S.; Schuchter, L.M.; et al. BRAF Inhibitor (BRAFi) Dabrafenib in Combination with the MEK1/2 Inhibitor (MEKi) Trametinib in BRAFi-Naive and BRAFi-Resistant Patients (pts) with BRAF Mutation-Positive Metastatic Melanoma (MM). In Proceedings of 2013 ASCO Annual Meeting, Chicago, IL, USA, 31 May–4 June 2013.
[63]
Burmeister, B.H.; Henderson, M.A.; Ainslie, J.; Fisher, R.; di Iulio, J.; Smithers, B.M.; Hong, A.; Shannon, K.; Scolyer, R.A.; Carruthers, S.; et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: A randomised trial. Lancet Oncol. 2012, 13, 589–597, doi:10.1016/S1470-2045(12)70138-9.
[64]
Henderson, M.A.; Burmeister, B.; Ainslie, J.; Fisher, R.; di Iulio, J.; Smithers, B.M.; Hong, A.; Shannon, K.F.; Scolyer, R.A.; Carruthers, S.; et al. Adjuvant Radiotherapy after Lymphadenectomy in Melanoma Patients: Final Results of an Intergroup Randomized Trial (ANZMTG 0.1.02/TROG 02.01). In Proceedings of 2013 ASCO Annual Meeting, Chicago, IL, USA, 31 May–4 June 2013.
[65]
Australian Institute of Health and Welfare. Cancer in Australia: An overview; AIHW: Canberra, Australia, 2010.
[66]
Bradford, P.T.; Freedman, D.M.; Goldstein, A.M.; Tucker, M.A. Increased risk of second primary cancers after a diagnosis of melanoma. Arch. Dermatol. 2010, 146, 265–272.
